Quoting IMS Health data, the company said the Renvela brand and generic had US sales of approximately USD 101 million for the most recent 12 months ending in October 2018.
Dr Reddy’s launches oral suspension drug in the US market
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain